{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2022,3,31]],"date-time":"2022-03-31T02:47:00Z","timestamp":1648694820634},"reference-count":33,"publisher":"Elsevier BV","issue":"10","license":[{"start":{"date-parts":[[2012,10,1]],"date-time":"2012-10-01T00:00:00Z","timestamp":1349049600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["La Presse M\u00e9dicale"],"published-print":{"date-parts":[[2012,10]]},"DOI":"10.1016\/j.lpm.2012.06.008","type":"journal-article","created":{"date-parts":[[2012,8,18]],"date-time":"2012-08-18T02:01:06Z","timestamp":1345255266000},"page":"1024-1030","source":"Crossref","is-referenced-by-count":8,"title":["Comment traiter une vascularite n\u00e9crosante\u00a0?"],"prefix":"10.1016","volume":"41","author":[{"given":"Lo\u00efc","family":"Guillevin","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"6","key":"10.1016\/j.lpm.2012.06.008_bib0005","doi-asserted-by":"crossref","first-page":"653","DOI":"10.1016\/j.lpm.2009.12.004","article-title":"Clinical trials on systemic necrotizing vasculitides","volume":"39","author":"Guillevin","year":"2010","journal-title":"Presse Med"},{"issue":"1","key":"10.1016\/j.lpm.2012.06.008_bib0010","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1097\/MD.0b013e318205a4c6","article-title":"The five factor score revisited: assessment of prognoses of systemic necrotizing vasculitides based on the French Vasculitis Study Group (FVSG) cohort","volume":"90","author":"Guillevin","year":"2011","journal-title":"Medicine (Baltimore)"},{"issue":"1","key":"10.1016\/j.lpm.2012.06.008_bib0015","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1097\/00002281-200201000-00005","article-title":"Assessing disease activity in the systemic vasculitides","volume":"14","author":"Luqmani","year":"2002","journal-title":"Curr Opin Rheumatol"},{"issue":"11","key":"10.1016\/j.lpm.2012.06.008_bib0020","first-page":"671","article-title":"Birmingham Vasculitis Activity Score (BVAS) in systemic necrotizing vasculitis","volume":"87","author":"Luqmani","year":"1994","journal-title":"QJM"},{"issue":"3","key":"10.1016\/j.lpm.2012.06.008_bib0025","doi-asserted-by":"crossref","first-page":"666","DOI":"10.1002\/1529-0131(200103)44:3<666::AID-ANR116>3.0.CO;2-A","article-title":"Long-term follow-up of polyarteritis nodosa, microscopic polyangiitis, and Churg-Strauss syndrome: analysis of four prospective trials including 278\u00a0patients","volume":"44","author":"Gayraud","year":"2001","journal-title":"Arthritis Rheum"},{"issue":"6","key":"10.1016\/j.lpm.2012.06.008_bib0030","first-page":"615","article-title":"Increased risk of Pneumocystis carinii pneumonia in patients with Wegener's granulomatosis","volume":"11","author":"Jarrousse","year":"1993","journal-title":"Clin Exp Rheumatol"},{"issue":"12","key":"10.1016\/j.lpm.2012.06.008_bib0035","doi-asserted-by":"crossref","first-page":"991","DOI":"10.1136\/ard.54.12.991","article-title":"Factors associated with Pneumocystis carinii pneumonia in Wegener's granulomatosis","volume":"54","author":"Godeau","year":"1995","journal-title":"Ann Rheum Dis"},{"issue":"5","key":"10.1016\/j.lpm.2012.06.008_bib0040","doi-asserted-by":"crossref","first-page":"1435","DOI":"10.1002\/art.30296","article-title":"Incidence and predictors of urotoxic adverse events in cyclophosphamide-treated patients with systemic necrotizing vasculitides","volume":"63","author":"Le Guenno","year":"2011","journal-title":"Arthritis Rheum"},{"issue":"6","key":"10.1016\/j.lpm.2012.06.008_bib0045","doi-asserted-by":"crossref","first-page":"488","DOI":"10.7326\/0003-4819-116-6-488","article-title":"Wegener granulomatosis: an analysis of 158\u00a0patients","volume":"116","author":"Hoffman","year":"1992","journal-title":"Ann Intern Med"},{"issue":"6","key":"10.1016\/j.lpm.2012.06.008_bib0050","first-page":"767","article-title":"Intravenous immunoglobulin in childhood cutaneous polyarteritis nodosa","volume":"16","author":"Gedalia","year":"1998","journal-title":"Clin Exp Rheumatol"},{"issue":"2","key":"10.1016\/j.lpm.2012.06.008_bib0055","doi-asserted-by":"crossref","first-page":"105","DOI":"10.2332\/allergolint.R-07-144","article-title":"Therapeutic strategies for systemic necrotizing vasculitides","volume":"56","author":"Guillevin","year":"2007","journal-title":"Allergol Int"},{"issue":"4","key":"10.1016\/j.lpm.2012.06.008_bib0060","doi-asserted-by":"crossref","first-page":"1186","DOI":"10.1002\/art.27340","article-title":"Treatment of polyarteritis nodosa and microscopic polyangiitis without poor-prognosis factors: a prospective randomized study of one hundred twenty-four patients","volume":"62","author":"Ribi","year":"2010","journal-title":"Arthritis Rheum"},{"issue":"1","key":"10.1016\/j.lpm.2012.06.008_bib0065","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1002\/art.10922","article-title":"Treatment of polyarteritis nodosa and microscopic polyangiitis with poor-prognosis factors: a prospective trial comparing glucocorticoids and six or twelve cyclophosphamide pulses in sixty-five patients","volume":"49","author":"Guillevin","year":"2003","journal-title":"Arthritis Rheum"},{"issue":"5","key":"10.1016\/j.lpm.2012.06.008_bib0070","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1097\/01.md.0000180792.80212.5e","article-title":"virus-associated polyarteritis nodosa: clinical characteristics, outcome, and impact of treatment in 115\u00a0patients","volume":"84","author":"Guillevin","year":"2005","journal-title":"Medicine (Baltimore)"},{"issue":"3","key":"10.1016\/j.lpm.2012.06.008_bib0075","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1056\/NEJMoa0909905","article-title":"Rituximab versus cyclophosphamide for ANCA-associated vasculitis","volume":"363","author":"Stone","year":"2010","journal-title":"N Engl J Med"},{"issue":"1","key":"10.1016\/j.lpm.2012.06.008_bib0080","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1056\/NEJMoa020286","article-title":"A randomized trial of maintenance therapy for vasculitis associated with antineutrophil cytoplasmic autoantibodies","volume":"349","author":"Jayne","year":"2003","journal-title":"N Engl J Med"},{"issue":"26","key":"10.1016\/j.lpm.2012.06.008_bib0085","doi-asserted-by":"crossref","first-page":"2790","DOI":"10.1056\/NEJMoa0802311","article-title":"Azathioprine or methotrexate maintenance for ANCA-associated vasculitis","volume":"359","author":"Pagnoux","year":"2008","journal-title":"N Engl J Med"},{"issue":"21","key":"10.1016\/j.lpm.2012.06.008_bib0090","doi-asserted-by":"crossref","first-page":"2381","DOI":"10.1001\/jama.2010.1658","article-title":"Mycophenolate mofetil vs azathioprine for remission maintenance in antineutrophil cytoplasmic antibody-associated vasculitis: a randomized controlled trial","volume":"304","author":"Hiemstra","year":"2010","journal-title":"JAMA."},{"issue":"1","key":"10.1016\/j.lpm.2012.06.008_bib0095","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1056\/NEJM199607043350103","article-title":"Trimethoprim-sulfamethoxazole (cotrimoxazole) for the prevention of relapses of Wegener's granulomatosis. Dutch Co-Trimoxazole Wegener Study Group","volume":"335","author":"Stegeman","year":"1996","journal-title":"N Engl J Med"},{"issue":"7","key":"10.1016\/j.lpm.2012.06.008_bib0100","doi-asserted-by":"crossref","first-page":"2180","DOI":"10.1681\/ASN.2007010090","article-title":"Randomized trial of plasma exchange or high-dosage methylprednisolone as adjunctive therapy for severe renal vasculitis","volume":"18","author":"Jayne","year":"2007","journal-title":"J Am Soc Nephrol"},{"key":"10.1016\/j.lpm.2012.06.008_bib0105","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1007\/978-1-4757-9182-2_84","article-title":"Pooled intravenous immunoglobulin in the management of systemic vasculitis","volume":"336","author":"Jayne","year":"1993","journal-title":"Adv Exp Med Biol"},{"issue":"1","key":"10.1016\/j.lpm.2012.06.008_bib0110","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1002\/art.23147","article-title":"Intravenous immunoglobulins for relapses of systemic vasculitides associated with antineutrophil cytoplasmic autoantibodies: results of a multicenter, prospective, open-label study of twenty-two patients","volume":"58","author":"Martinez","year":"2008","journal-title":"Arthritis Rheum"},{"issue":"4","key":"10.1016\/j.lpm.2012.06.008_bib0115","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1056\/NEJMoa041884","article-title":"Etanercept plus standard therapy for Wegener's, granulomatosis","volume":"352","year":"2005","journal-title":"N Engl J Med"},{"issue":"10","key":"10.1016\/j.lpm.2012.06.008_bib0120","doi-asserted-by":"crossref","first-page":"1126","DOI":"10.1093\/rheumatology\/41.10.1126","article-title":"Efficacy of the anti-TNF-alpha antibody infliximab against refractory systemic vasculitides: an open pilot study on 10\u00a0patients","volume":"41","author":"Bartolucci","year":"2002","journal-title":"Rheumatology (Oxford)"},{"issue":"3","key":"10.1016\/j.lpm.2012.06.008_bib0125","doi-asserted-by":"crossref","first-page":"717","DOI":"10.1097\/01.ASN.0000114554.67106.28","article-title":"Prospective study of TNFalpha blockade with infliximab in antineutrophil cytoplasmic antibody-associated systemic vasculitis","volume":"15","author":"Booth","year":"2004","journal-title":"J Am Soc Nephrol"},{"issue":"9","key":"10.1016\/j.lpm.2012.06.008_bib0130","doi-asserted-by":"crossref","first-page":"1343","DOI":"10.1136\/ard.2007.083584","article-title":"Infliximab efficacy and safety against refractory systemic necrotising vasculitides: long-term follow-up of 15\u00a0patients","volume":"67","author":"Josselin","year":"2008","journal-title":"Ann Rheum Dis"},{"issue":"7","key":"10.1016\/j.lpm.2012.06.008_bib0135","first-page":"1371","article-title":"Refractory polyarteritis nodosa successfully treated with infliximab","volume":"32","author":"Al-Bishri","year":"2005","journal-title":"J Rheumatol"},{"issue":"2","key":"10.1016\/j.lpm.2012.06.008_bib0140","doi-asserted-by":"crossref","first-page":"586","DOI":"10.1002\/art.23198","article-title":"Treatment of Churg-Strauss syndrome without poor-prognosis factors: a multicenter, prospective, randomized, open-label study of seventy-two patients","volume":"58","author":"Ribi","year":"2008","journal-title":"Arthritis Rheum"},{"issue":"4","key":"10.1016\/j.lpm.2012.06.008_bib0145","doi-asserted-by":"crossref","first-page":"686","DOI":"10.1002\/art.22679","article-title":"Churg-Strauss syndrome with poor-prognosis factors: a prospective multicenter trial comparing glucocorticoids and six or twelve cyclophosphamide pulses in forty-eight patients","volume":"57","author":"Cohen","year":"2007","journal-title":"Arthritis Rheum"},{"issue":"9","key":"10.1016\/j.lpm.2012.06.008_bib0150","doi-asserted-by":"crossref","first-page":"632","DOI":"10.7326\/0003-4819-143-9-200511010-00006","article-title":"Antineutrophil cytoplasmic antibodies and the Churg-Strauss syndrome","volume":"143","author":"Sable-Fourtassou","year":"2005","journal-title":"Ann Intern Med"},{"issue":"6","key":"10.1016\/j.lpm.2012.06.008_bib0155","doi-asserted-by":"crossref","first-page":"1336","DOI":"10.1016\/j.jaci.2010.03.028","article-title":"Mepolizumab as a steroid-sparing treatment option in patients with Churg-Strauss syndrome","volume":"125","author":"Kim","year":"2010","journal-title":"J Allergy Clin Immunol"},{"issue":"1\u00a0Suppl. 57","key":"10.1016\/j.lpm.2012.06.008_bib0160","first-page":"24","article-title":"Interferon-alpha for maintenance of remission in Churg-Strauss syndrome: a long-term observational study","volume":"28","author":"Metzler","year":"2010","journal-title":"Clin Exp Rheumatol"},{"issue":"5","key":"10.1016\/j.lpm.2012.06.008_bib0165","doi-asserted-by":"crossref","first-page":"370","DOI":"10.7326\/0003-4819-129-5-199809010-00004","article-title":"Interferon-alpha treatment of four patients with the Churg-Strauss syndrome","volume":"129","author":"Tatsis","year":"1998","journal-title":"Ann Intern Med"}],"container-title":["La Presse M\u00e9dicale"],"original-title":[],"language":"fr","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0755498212003971?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0755498212003971?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,11,21]],"date-time":"2018-11-21T06:30:05Z","timestamp":1542781805000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0755498212003971"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,10]]},"references-count":33,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2012,10]]}},"alternative-id":["S0755498212003971"],"URL":"https:\/\/doi.org\/10.1016\/j.lpm.2012.06.008","relation":{},"ISSN":["0755-4982"],"issn-type":[{"value":"0755-4982","type":"print"}],"subject":[],"published":{"date-parts":[[2012,10]]}}}